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What’s already known about this topic?  
Keratinocyte cancers (KCs) are the most common cancer affecting Caucasian populations. 
The incidence of Basal Cell Carcinoma (BCC) and cutaneous Squamous Cell Carcinoma (cSCC) is 
increasing worldwide including the UK, most commonly in elderly male Caucasian patients. These 
cancers are traditionally substantially under-reported and frequently excluded from national cancer 
statistics. 
 
What does this study add? 
Using improved data collection methods in England and validated, tumour reporting techniques, we 
report the most accurate BCC and cSCC incidence data for the UK ever published. 
Identifying the 1st BCC and cSCC per patient per annum, the incidence of BCC and cSCC in the UK 
(excluding Wales) was 285 and 77 per 100,000 person-years respectively between 2013 and 2015, 
with more than 210,000 KCs in the UK in 2015. 
 
Abstract 
Background 
Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), together known as 
keratinocyte cancers (KCs), are the commonest cancer in Caucasian populations. Recent 
improvements to registry data collection in England has allowed more accurate analysis of the 
epidemiology of BCC and cSCC and for the first time we are able to provide an accurate 
(representative) tumour burden for KC in the UK.  
Objective  
To estimate the incidence of BCC and cSCC in the UK. 
Methods 
A cohort of patients with KCs between 2013 and 2015 were identified using linkage to diagnostic 
codes derived from pathology reports collected into the national cancer registry. Data from 
England’s cancer registry were combined with data from Scotland, Northern Ireland and Wales. 
European Age Standardised incidence rates (EASRs) of the first BCC and cSCC per patient per annum 
(PPPA) were calculated.  
Results 
In the UK, the EASR of the first BCC and cSCC PPPA 2013-2015 were 285 and 77 per 100,000 person-
years respectively (211,120 KCs total in 2015). The mean annual percentage increase was 5% 
between 2013-2015 for both BCC and cSCC. By counting the first tumour per patient per year, we 
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include an additional 51% KCs compared to the previous reporting technique which counts only the 
first BCC and cSCC in a patient’s lifetime, yet it represents a probable underestimation of 5-11% of 
the true tumour count.  
 
Conclusions 
Based on an improved methodology, a more representative incidence of KC is presented, which is 
essential to healthcare planning and will lead to improved understanding of the epidemiology of KC. 
 
 
Introduction: 
Keratinocyte cancers (KCs), the collective term for basal cell carcinomas (BCCs) and cutaneous 
squamous cell carcinomas (cSCCs), are the most common cancers in the UK and the most common 
cancer in white ethnic populations worldwide. However, epidemiological data in the UK have 
historically been of relatively poor quality. [1-5] Due to high volume and multiplicity of KCs, they 
have frequently been excluded from national cancer registries and statistics. Previous studies have 
reported that incidence rates of KC are increasing worldwide and evidence from local audits suggest 
that the rate of increase in the UK may be higher than in European counterparts [6-13]. Increasing 
tumour incidence is presumed to be a result of an ageing population, increased ultraviolet (UV) 
radiation exposure with easier access to travel abroad and a higher proportion of fairer skin types in 
the UK compared to other countries, [6, 14] but little is known about the epidemiology of KC in the 
UK.  
The healthcare workload burden and cost of KC is substantial within dermatology departments in 
the UK, where these cancers are often seen urgently, within two weeks of referral. In 2008, skin 
cancer management costs were estimated to be between £106–£112 million and approximately 
£889 - £1226 per KC in England.[15] A decade later, these estimates are likely to be substantially 
higher, with advances in treatment approaches and increase in patient volume. Furthermore, 
despite a relatively low mortality, morbidity through cosmetic disfigurement and functional 
morbidity is considerable given that KCs are frequently multiple and most commonly located on the  
face. 
Despite the high volume and associated costs of KC, limited research progress has been reported. 
This discrepancy was highlighted by a UK Translational Research Network in Dermatology (UKTREND) 
e-DELPHI exercise which assessed the research needs of clinicians in the UK and identified research 
into KC as a priority area.[16] 
In 1999, the United Kingdom and Ireland Association of Cancer Registries (UKIACR ) ruled that due to 
complexities in registering multiple pathology reports accurately, only the first BCC or cSCC per 
patient is reported, despite all pathology reports now being routinely collected since 2013 in 
England, Scotland and Northern Ireland.[17] This rule is also used in many cancer registries 
worldwide.[6] The impact of this registration approach was that previous figures were clearly 
significant underestimations of national incidence in UK. Metachronous and synchronous BCCs and 
cSCCs are common[18]. After a diagnosis of BCC, the 3 year risk of a subsequent BCC is estimated to 
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be 44%, with 10% developing a further BCC within 6 months [10, 19-21]. Likewise, after an initial 
cSCC, the 5 year risk of a further cSCC is estimated to be 37% [21]. Previous studies have shown that 
when counting all BCCs as opposed to the 1st registered BCC, an additional 30-50% of tumours are 
counted [10, 22, 23, 24]. Changes in cancer registration processes in England, including the 
introduction of national automated registration have enabled the development of a more 
comprehensive BCC and cSCC dataset for the first time.  
The objective of this study was to validate improved data collection methods and report the 
incidence and survival for BCC and cSCC from the cancer registry data at a national level for the first 
time.  
 
Materials and methods:  
Study design, setting and participants: 
Data were provided by the National Cancer Registration and Analysis Service (NCRAS), England. It is 
mandatory for all NHS pathology laboratories, and recommended to all private pathology 
laboratories in England, to provide all cancer pathology to NCRAS and NCRAS data quality teams 
ensure pathology laboratories are compliant. These pathology reports are combined with 
information from the Patient Administration System (PAS) and Cancer Outcomes and Services 
Dataset (COSD) to form a cancer registration record. Since 2013 in England this process became 
nationalised and mostly automated; a majority of tumours are registered based upon the pathology 
report laboratory codes and text information provided. The minority which do not meet the 
automated processor’s selection criteria are manually registered. 
BCC and cSCC were identified using the ICD-10 (International Classification of Diseases) site codes 
and ICD-02 morphology and behaviour codes (supplementary table). The date of receipt of the 
pathology sample was used as the date of diagnosis, to identify the first BCC and cSCC per patient 
per annum (PPPA).  
Data were also provided by Information Services Division Scotland, the Northern Ireland cancer 
registry and the Welsh Cancer Intelligence & Surveillance Unit (WCISU). Welsh data collection is 
acknowledged by the registry to be incomplete (personal communication with WCISU), awaiting 
changes to be enforced from 2016 data onwards. Welsh data were therefore excluded from the 
analyses, except for overall tumour count.  
Validation 
To confirm the accuracy of the data and the use of the first PPPA technique, a randomised selection 
of 500 BCC patients and 500 cSCC patients in 2013 in England were reviewed by a single 
dermatologist [ZV]. Tumours diagnosed in the previous calendar year, recurrences of previous 
tumours and incorrectly coded tumours were excluded e.g. Bowens disease. Additional tumours 
collected but not counted with the first PPPA technique (i.e. more than one tumour per annum) 
were analysed to provide an estimate of how the first PPPA compares to manually registering all 
tumours per patient and also to assess the validity of the registration process in England.  
Furthermore, in Scotland, because all cSCCs are registered except in specific cases such as patients 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
with genetic predisposition to multiple cSCCs, Scottish data was also used to assess the first PPPA 
technique vs registering all tumours manually. 
Variables 
Patient demographics such as age (taken as a continuous variable taken from day of diagnosis), sex 
and self reported ethnicity were analysed from NCRAS which derives information from PAS and 
COSD. Deprivation quintiles were calculated using the patient’s Lower Super Output Area at 
diagnosis linked to the Index of Multiple Deprivation 2015.[25]   
Statistical analysis 
The NCRAS data were extracted using an Oracle SQL developer© Version 4.1.5.21 (Oracle, California, 
USA). Microsoft© excel version 2010 (Microsoft, California, USA) and Stata© version 14 (Stata 
Corporation, College Station, TX, USA) were used for statistical analyses. Randomisation as listed 
above was performed using random number generator from Excel© 2010.  
European Age-adjusted incidence rates (EASR) are weighted based upon European standard 
populations 2013 in 5 year age bands. The EASR of cSCC and BCC 1st PPPA were calculated across 
gender and nations (England, Scotland and Northern Ireland). Welsh data were excluded from EASR 
and age specific rates due to lack of completeness. The estimated annual percentage changed 
(EAPC) was calculated as the mean change in EASR per year. 
Statistics for absolute number of deaths attributed to non-melanoma skin cancer was as reported by 
the Office of National Statistics.[26] 
The Pohar-Perme estimator was used to calculate age-standardised net survival with the 'stns' 
command in Stata 14. This analysis was age-standardised using weights from the International 
Cancer Survival Standard (ICSS)[27] i.e. survival was standardised based upon expected survival of 
age and sex specific groups. Life tables were obtained from the Cancer Survival Group at the London 
School of Hygiene and Tropical Medicine. Vital status of patients was determined until 31st 
December 2016. [28] 
 
Results:  
 
Validation 
Overall, an additional 51% KC tumours were identified using first PPPA technique compared to 
identifying only the first incident tumour of all time. Analysing the first BCC PPPA in England 2013-
2015 (n=410,716) compared to 1st registered (n=268565) resulted in 53% further BCC tumours 
recorded over 3 years. Likewise, when counting first PPPA cSCC (n=104529) compared to 1st 
registered (n=76977) an additional 36% cSCC tumours were recorded.  
To assess the 1st PPPA technique and use of an automated processor in England, a randomly selected 
cohort of 500 BCC and 500 cSCC patients from the English cancer registry in 2013 were selected and 
the number of tumours per patient was counted. Counting the first tumour PPPA resulted in 10.6% 
fewer BCC tumours and 6.8% fewer cSCC tumours, figure 1. 
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In Scotland, all cSCC tumours are registered manually except cases of genetic predisposition, 
therefore we compared the registered cSCC tumour count to the 1st PPPA technique in Scotland. This 
found an underestimation 5.3% of all cSCCs by using the 1st PPPA, figure 1.  
Analysing the automated processing technique in England, only 0.8% (8/1000) tumours were 
incorrectly coded e.g. Bowens disease coded as an invasive cSCC.   
 
UK Incidence of KC 
The absolute 1st PPPA BCC count increased in the three year period from 145,817 to 166,448 in 
2015, figure 2. The EASR of 1st PPPA BCC in the UK from 2013-2015 was 352/100,000 Person Years 
(PY) in males and 219/100,000 PY in females. More than 85% of BCCs in the UK occurred in England 
and the EASR was highest in England compared to other UK nations, figure 2. For the UK, the 
Estimated Annual Percentage Change (EAPC) was 5% for BCC, but much lower in Northern Ireland 
(0.3%).  
 
The absolute cSCC count of 1st PPPA increased from 38,664 in 2013 to 44,672 in 2015 in the UK, 
figure 2. The EASR of 1st PPPA cSCC from 2013-2015 was 111 in men and 42/100,000 PY in women 
with highest rates seen in Northern Ireland, figure 2. The EAPC of cSCC was around 6% in the three 
year period.  
 
Geographic incidence differences in UK: 
The incidence rates of 1st PPPA KC differ across the UK and are highest in southern and coastal 
regions, figure 3. The highest BCC rates were observed in Southwest England (EASR 362/100,000 PY) 
and the lowest EASR was in Dumfries and Galloway (39/100,000 PY). For cSCC, the highest rates 
were observed in Southwest England and the lowest in Shetland (EASR 107 and 345 /100,000 PY, 
respectively). Several regions such as London and have notably lower EASR as expected. 
Demographics of KC patients in England 
1st all-time BCC and cSCC patients were more commonly males, with a male: female ratio 1.2:1 for 
BCC and 1.7:1 for cSCC, table 1. The median age at time of incident tumour was approximately 71 
years (interquartile range (IQR) =62-80) for BCC and 79 years (IQR 71-85) for cSCC. The age specific 
rates for both BCC and cSCC clearly increase with age and are much higher and steeper among men 
than women, figure 4. For both BCC and cSCC, fewer than 1% of individuals self-reported as non-
white, with a substantial proportion of missing data (up to 34%). The distribution of the deprivation 
quintiles is comparable for both tumour types between men and women.  
 
Body site of KCs in England 
The majority of KCs are located in the head and neck region, especially on the face (between 27% 
and 40.9%; table 1). Compared to cSCCs, BCCs tend to be more common on the trunk and are less 
frequent on the upper extremities. In men, 15.8% of cSCCs were located on the ear whereas the ear 
was affected in only 1.3% of women. A quarter of cSCCs in women were located on the lower 
extremities, which is five-fold more than in men. In approximately 15% of BCCs and 5% of cSCCs, 
body site was not reported, table 1. 
 
KC specific mortality in England:  
The absolute number of deaths with an underlying cause of ‘non melanoma skin cancers’ (which 
includes other skin cancers such as Merkel cell carcinomas) in England were 489 in 2013, 626 in 2014 
and 624 in 2015. 
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Three year net survival was 101.9% (95% CI 101.8-102.0) for BCC and 96.2% (CI 95.9-96.6) for cSCC 
overall. For men, three year net survival was 101.9% (95% CI 101.8-102.1) for BCC and 95.7% (95% CI 
95.3-96.2) for cSCC. For women, three year net survival was 101.9% (95% CI 101.7-102.0) for BCC 
and 97.1% (96% CI 96.6-97.6) for cSCC. 
 
 
Discussion: 
We report the largest and most complete dataset for national incidence of KC ever published, with 
over 210,000 tumours reported in 2015 in the UK. With significant increases in tumour count 
between 2013 and 2015, KCs represent an overwhelming burden on the workload of healthcare 
resources. KCs occur mainly in older people, and because of steadily aging populations, the pressure 
on the health service is likely to further increase. Of note, skin cancers are four times more common 
than any other cancer in the UK in 2015.[26] This study provides much needed information, as 
highlighted in recent epidemiological reviews of KC [3, 7-9, 29]. 
Due to the frequent multiplicity of KCs, the UKIACR method of only counting one tumour per patient 
has resulted in substantial underestimation of national tumour counts. We validate a technique to 
assess 1st PPPA BCC and cSCC that identified 51% additional tumours compared to the standard first 
registered BCC and cSCC UKIACR method. While less accurate than manually registering all KCs, this 
method allows improved incidence reports with minimal additional workload and is easily achievable 
with access to pathology or cancer registry data. Our validation study would imply that when 
counting all tumours i.e multiple tumours per patient per year, true tumour count is likely to be 5-
10% higher than those provided by the 1st PPPA technique.   
Strengths and Limitations: 
The combined UK registries form the largest population based KC registry in the world; an essential 
tool for assessing the epidemiology of these tumours and the main strength of our study. However, 
inherent to large national pathology based cancer registries there are several potential sources of 
under-reporting such as use of topical and destructive treatments without histological confirmation, 
miscoding or the impact of long waiting lists. Also, there are regional differences in KC registration 
within the UK which may have affected comparisons between regions. For example, all cSCCs are 
manually registered in Scotland therefore rates will be comparatively higher than 1st PPPA counts, 
despite this; rates remain lower than England and Northern Ireland. Due to the introduction of new 
automated report processing technology in 2013, the data collection prior to 2013 may be less 
complete. Therefore the increase in first registered tumours in subsequent years may be an 
overestimation, but this does not apply to 1st PPPA reporting. Since the KC registry is based on 
routinely collected data and linked to other national data sources, the granularity of the data is not 
always sufficient e.g. missing data in self-reported ethnicity, tumour localisation and lack of UV 
radiation exposure data.        
Primary cSCC affecting perianal sites have a different pathogenesis, with human papillomavirus 
infection thought to be an important cause rather than UV radiation [30]. However, ICD-10 coding of 
perianal tumours classifies these to be coded as ‘truncal’ tumours and therefore this precludes 
accurate identification of these tumours. 
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Interpretation:  
 
The distribution of recorded anatomical sites for primary KCs differed between men and women, 
which is in line with other studies [4, 20]. This may relate to varying UV radiation exposure as a result 
of male pattern baldness and cultural preferences, i.e. shorter hair for men and women wearing 
dresses/skirts. This may explain why men are more likely to develop KCs on the ear and scalp, and 
for women the lower limb is preferentially affected. However, the commonest site in both sexes for 
KC was the face. 
The regional variations identified in KC incidence may reflect reducing incidence with higher 
latitude/lower UV exposure. In addition, in urban areas ethnicity may be more diverse, and 
behaviour may differ in terms of outdoor work and activities, figure 3. It is unclear why Northern 
Ireland has a higher cSCC incidence compared to other nations, this could relate to a higher number 
of outdoor occupations, recent public health campaigns, variation in clinical practice or data 
collection.[31, 32] Compared to elsewhere in the world, incidence rates of KC in the UK are lower 
than those published in Australia, but higher than elsewhere in Europe and USA with varying rates 
presumably due to skin type/genetic predisposition and UV radiation exposure. [6, 10, 18, 24] 
Similar to previous studies, we show that BCC and cSCC are both significantly associated with lower 
deprivation quintiles[33]. This is likely to be the result of the expense of foreign travel and increased 
leisure time being more affordable in these quintiles, equating to higher UV exposure in the 
generations affected as well as increased awareness of skin cancer and access to healthcare. 
According to national statistics, 86% of the population in England and Wales are of ‘white’ ethnicity, 
however of those with known ethnicity, 99.3% of primary cSCC patients are of white ethnicity, which 
may be mainly due to these skin types having reduced protection from UV radiation.[34] 
Although the net survival of over 95% for both types of KC the overall prognosis of KC is very good, 
only a minority of cSCC patients develops advanced disease. Despite low mortality rates, KCs 
represent an overwhelming tumour burden in the population.[35] We confirm an interesting 
observation that patients who develop their first BCC have a 3 year net survival of over 100%.[36] 
This can be in part the result of the association of BCC with lower deprivation quintiles, fitness for 
biopsy excluding older more frail patients from our cohort and general adherence to healthier 
outdoors lifestyles. Figure 4 shows that at the age of 85 a peak in incidence rate occurs, suggesting 
that patients where the risk outweighs benefit for BCC treatment are excluded, i.e. frailer, older 
patients with more comorbidities.  
 
Conclusion 
A new technique taking advantage of the modernisation of national cancer registration and data 
collection in the UK has resulted in significantly improved reporting of KC incidence. We have 
validated this registration and data collection approach here and now demonstrate more accurately 
the huge and steadily increasing trend in KC incidence in the UK. This scale of the disease burden 
posed by KC inevitably has implications for healthcare resources. The more accurate incidence data 
reported here and now available prospectively through improved KC registration will undoubtedly 
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facilitate improved service planning and provision in the future. In addition, it will lead to improved 
understanding of the natural history and prognosis of KC. Finally, it provides further evidence for the 
importance of future skin cancer prevention initiatives as part of strategies to reduce the morbidity 
and future healthcare resource implications of KC. 
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Legends: 
Figure 1. Analysis of 1st tumour per patient per annum technique for counting keratinocyte cancers 
from registry data 
Figure 2a-d. National tumour count and incidence rate of basal cell carcinoma (BCC) and cutaneous 
squamous cell carcinoma (cSCC) using the 1st tumour per patient per annum technique except for 
cSCC data for Scotland where all cSCC are registered, Welsh data are excluded from incidence rates 
due to incomplete data collection. 2a. National BCC tumour count 2013-2015. 2b. National age 
standardised incidence rate of BCC 2013-2015. 2c. National cSCC tumour count 2013-2015. 2d. 
National age standardised incidence rate of cSCC 2013-2015. 
Figure 3a. Regional basal cell carcinoma age standardised incidence rates in UK 2013-2015 using the 
1st tumour per patient per annum technique. Welsh data are excluded due to incomplete data 
collection. 3b. Regional cutaneous squamous cell carcinoma (cSCC) age standardised incidence rates 
in UK 2013-2015 using the 1st tumour per patient per annum technique except in Scotland where all 
cSCC are registered. Welsh data are excluded due to incomplete data collection. 
Figure 4a-b Age specific rates of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma 
(cSCC) in males and females 2013-2015, England. Using data for 1st tumour all time. 4a. Age specific 
rates of BCC. 4b. Age specific rates of cSCC. 
Supplementary Table. Classification of basal cell carcinoma and cutaneous squamous cell carcinoma  
Table 1 Patient demographics of 1st registered basal cell carcinoma and cutaneous squamous cell 
carcinoma in England 2013-2015 
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Patient demographics of 1
st
 
registered tumour 
1
st
 BCC n=268565    1
st
 cSCC n=76977   
Male  
n=144680 
Female 
n=123885 
Male  
n=48254 
Female 
n= 28723 
Age Median (IQR) years 72 (63-79) 71 (60-80) 78 (71-84) 80 (71-87) 
Age 
0-29 
30-39 
40-49 
50-59 
60-69 
70-79 
80-89 
90+ 
464 0.3% 
2229                       1.5% 
7685                       5.3% 
16660 11.5% 
35487 24.5% 
46551 32.2% 
30631 21.3% 
4973 3.4% 
641 0.5% 
3066                       2.5% 
9680                       7.8% 
16148 13.0% 
27893 22.5% 
33990 27.4% 
25913 20.9% 
6554 5.3% 
30 0.1% 
123                         0.3% 
655                         1.4% 
2117 4.4% 
7352 15.2% 
16158 33.5% 
17822 36.9% 
3997 8.3% 
26 0.1% 
98 0.3% 
489                         1.7% 
1491 5.2% 
3930 13.7% 
7735 26.9% 
10385 36.2% 
4569 15.9% 
Ethnicity  
white 
mixed 
Indian/ other asian 
background 
Afrocaribbean/other black 
background 
Chinese 
Other ethnic group 
Unknown 
 
97418 67.3% 
63 0.0% 
108 0.1% 
  
57 0.0% 
  
22 0.0% 
402 0.3% 
46610 32.2% 
 
80690 65.1% 
69 0.1% 
114 0.1% 
 
61 0.0% 
 
23 0.0% 
371 0.3% 
42557 34.4% 
 
43283 89.7% 
29 0.1% 
73 0.2% 
 
42 0.1% 
 
7 0.0% 
169 0.4% 
4651 9.6% 
 
25226 87.8% 
22 0.1% 
50 0.2% 
 
38 0.1% 
 
8 0.0% 
96 0.3% 
3283 11.4% 
Deprivation Quintiles 
1 (least deprived) 
2 
3 
4 
5 (most deprived) 
 
40366                    27.9% 
37363                    25.8% 
30101                    20.8% 
21915                    15.1% 
14935                    10.3% 
 
32572                     26.3% 
31004                     25.0% 
26108                     21.1% 
20045                     16.2% 
14156                     11.4% 
 
12792  26.5% 
12451                     25.8% 
10200                     21.1% 
7642                        15.8% 
5169                        10.7% 
 
7096                       24.7% 
7064                       24.6% 
6295                       21.9% 
4825                       16.8% 
3443                       12.0% 
Site of 1st registered BCC or 
cSCC  
Lip (cutaneous) 
Eyelid incl. canthus 
Ear 
Face 
Scalp/Neck 
Trunk incl. perianal 
Upper limb incl.  shoulder 
Lower limb incl. hip 
Skin NOS 
 
 
1491 1.0% 
6353 4.4% 
9439 6.5% 
55213 38.2% 
11315 7.8% 
22630 15.6% 
9870 6.8% 
5637 3.9% 
22732 15.7% 
 
 
3219 2.6% 
8019 6.5% 
1568 1.3% 
50691 40.9% 
8265 6.7% 
14484 11.7% 
7479 6.0% 
10951 8.8% 
19209 15.5% 
 
 
815 1.7% 
584 1.2% 
7601 15.8% 
13126 27.2% 
11566 24.0% 
3080 6.4% 
6947 14.4% 
2367 4.9% 
2168 4.5% 
 
 
679 2.4% 
483 1.7% 
363 1.3% 
9308 32.4% 
1669 5.8% 
2201 7.7% 
5416 18.9% 
7205 25.1% 
1399 4.9% 
 
CI = confidence interval IQR=Interquartile range NOS = Not Otherwise Specified 
 
Table 1. Patient demographics of 1st all-time registered basal cell carcinoma and cutaneous squamous cell carcinoma, England 2013-2015. 
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2a. National BCC tumour count, 2013-2015.  
UCI = Upper Confidence Interval 95% LCI = Lower Confidence Interval 95% 
2b. National age standardised incidence rate of BCC, 2013-2015 
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2c. National cSCC tumour count, 2013-2015 
 
UCI = Upper Confidence Interval 95% LCI = Lower Confidence Interval 95% 
2d. National age standardised incidence rate of cSCC 2013-2015 
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Figure 2a-d. National tumour count and incidence rate of basal cell carcinoma (BCC) and 
cutaneous squamous cell carcinoma (cSCC) using the 1
st
 tumour per patient per annum 
technique except for cSCC data for Scotland where all cSCC are registered, Welsh data is 
excluded from incidence rates due to incomplete data collection. 2a. National BCC tumour count 
2013-2015. 2b. National age standardised incidence rate of BCC 2013-2015. 2c. National cSCC 
tumour count 2013-2015. 2d. National age standardised incidence rate of cSCC 2013-2015. 
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4a. Age specific rates of BCC 
  
4b. Age specific rates of cSCC  
Figure 4a-b Age specific rates of basal cell carcinoma (BCC) and cutaneous squamous cell 
carcinoma (cSCC) in males and females 2013-2015, England. Using data for 1st tumour all time. 
4a. Age specific rates of BCC. 4b. Age specific rates of cSCC 
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